Mixed Connective Tissue Disease

MCTD Introduction - The Great Overlap

• MCTD: A distinct systemic autoimmune rheumatic disease, often termed an "overlap syndrome."
• Key characteristic: Combines clinical features typically seen in:
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)
  • Polymyositis (PM) and/or Dermatomyositis (DM)
• Initial presentation can be as Undifferentiated Connective Tissue Disease (UCTD).
• Disease course: May remain stable MCTD or evolve into a more defined CTD over time.
• Serological hallmark: Presence of high titers of antibodies to U1 ribonucleoprotein (anti-U1 RNP).

  ⭐ MCTD is characterized by high titers of anti-U1 RNP antibodies. oka

MCTD Pathophysiology - Immune System Mix-up

• Immune Dysregulation: Central defect; involves hyperactive T-cells & B-cells, leading to loss of self-tolerance.
• Autoantibody Production: Key feature is high-titer anti-U1-RNP antibodies.
  • These antibodies recognize specific proteins (70kD, A, C) on U1 small nuclear ribonucleoprotein (snRNP) particles, crucial for mRNA splicing.
• Mechanism of Damage: Not fully elucidated but involves:
  • Immune complex deposition.
  • Complement activation.
  • Endothelial cell injury & T-cell mediated cytotoxicity.
• Result: Inflammation & damage in various connective tissues.

⭐ Anti-U1-RNP antibodies target the 70-kD, A, and C proteins of the U1 small nuclear ribonucleoprotein particle.

MCTD Clinical Features - A Symptom Medley

• Hallmarks (Often Initial):
  • Raynaud's phenomenon: Vasospasm of digits; nearly 100% prevalence.
  • Swollen hands/Puffy fingers: Diffuse swelling ("sausage digits"), may evolve to sclerodactyly.
• Musculoskeletal:
  • Arthralgia/Polyarthritis: Symmetric, non-erosive; Jaccoud's arthropathy (deforming but reducible) possible.
  • Inflammatory Myositis: Proximal muscle weakness, tenderness; elevated CK.
• Systemic Manifestations:
  • Esophageal dysmotility: Dysphagia for solids/liquids, reflux.
  • Pulmonary: Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH) - significant morbidity/mortality.
  • Cardiac: Pericarditis most common; myocarditis, conduction defects.
  • Renal: Mild glomerulonephritis (membranous nephropathy commonest).
  • Neurologic: Trigeminal neuropathy is the most frequent CNS finding.
• Skin (Overlap Features):
  • SLE-like: Malar rash, photosensitivity.
  • SSc-like: Sclerodactyly, calcinosis cutis.
  • DM-like: Gottron's papules (less common).

⭐ Raynaud's phenomenon is an almost universal presenting feature in MCTD.

MCTD Diagnosis - Pinpointing the Puzzle

• Diagnosis combines clinical criteria and specific serology.
  • Commonly used criteria: Alarcon-Segovia, Kasukawa, Sharp.
• Clinical Presentation:
  • Requires ≥2 CTD features (SLE, SSc, PM/DM).
  • Key manifestations: Raynaud's phenomenon, swollen hands/puffy fingers, arthralgia/arthritis, myositis, esophageal dysmotility, acrosclerosis.
• Serological Hallmark:
  • Essential: High-titer anti-U1 RNP antibodies (specifically U1 small nuclear ribonucleoprotein).
  • ANA: Typically high-titer, speckled pattern.

⭐ High-titer anti-U1 RNP is essential for diagnosis, often in the absence of other specific autoantibodies like anti-dsDNA or anti-Scl-70.

• Supportive Serology:
  • Other disease-specific autoantibodies (e.g., anti-dsDNA, anti-Sm, anti-Scl-70, anti-centromere, anti-Jo-1) typically absent or in low titers.

MCTD Management - Taming the Tempest

• Goal: Symptom control & organ protection.
• Mild disease (arthralgia, myalgia, rash):
  • NSAIDs, Hydroxychloroquine (HCQ)
  • Low-dose corticosteroids
• Moderate-Severe disease (organ involvement):
  • High-dose corticosteroids
  • Immunosuppressants (Methotrexate, Azathioprine, Mycophenolate mofetil)
  • Biologics (e.g., Rituximab) for refractory cases.
• Raynaud's: Calcium channel blockers, lifestyle changes.
• Pulmonary Hypertension: Vasodilators (PDE5-inhibitors, ERAs, prostanoids).

⭐ Pulmonary hypertension is a major cause of mortality in MCTD.

• Regular follow-up is crucial for monitoring disease activity and complications.

High‑Yield Points - ⚡ Biggest Takeaways

• MCTD is a distinct overlap syndrome with features of SLE, systemic sclerosis, and polymyositis/dermatomyositis.
• Serological hallmark: Presence of high-titer anti-U1 RNP antibodies.
• Frequent early manifestations: Raynaud's phenomenon, swollen hands or puffy fingers, and arthralgias.
• Pulmonary hypertension is a critical complication and a leading cause of mortality.
• Other significant involvements include arthritis, myositis, esophageal dysmotility, and interstitial lung disease.
• Often referred to as Sharp's syndrome.